Abstract Body

Background: GSK1265744 (GSK744) long-acting (LA) is a strand-transfer inhibitor of HIV/SIV integrase (InSTI) formulated as a 200 mg/mL injectable nanoparticle suspension. GSK744 LA is an effective pre-exposure prophylaxis (PrEP) agent against repeated low-dose intrarectal SHIV exposures in male rhesus macaques. This study was performed to evaluate the effectiveness of GSK744 LA as PrEP against high-dose intravaginal SHIV challenges. Methodology: Twelve female rhesus macaques were injected intramuscularly (IM) with 30 mg Depo Provera on weeks -3 and 2 to synchronize the menstrual cycle and thin the cervicovaginal epithelium. Eight macaques were injected IM with 50 mg/kg GSK744 LA on weeks 0 and 4, and 4 macaques remained untreated as controls. All 12 macaques were challenged intravaginally with high dose SHIV162P3 (300 TCID50) on week 1. GSK744 LA-treated macaques were further challenged with the same dose of virus at weeks 5 and 7. Infection status was monitored weekly by quantifying viral RNA (vRNA) in plasma. Plasma GSK744 concentrations were measured weekly by HPLC-MS/MS. Results: All 4 control macaques became infected after a single high-dose challenge. Plasma vRNA was detected in control macaques 1 to 2 weeks after the first challenge (see figure). Of the 8 GSK744 LA-treated macaques, six remained aviremic through week 24 (p=0.0003, log-rank test). In the two GSK744 LA-treated macaques that became infected, plasma vRNA was detected 3 and 7 weeks after the last challenge. Consensus sequencing of the integrase-coding region showed breakthrough infections were initiated with wild-type virus, and no drug resistant mutation was identified. Drug concentrations at the time of vRNA detection were 0.15 or 0.37 μg/mL GSK744, respectively. Further investigation of the protective mechanism versus route of infection and virus titers may be warranted. In the aviremic macaques, GSK744 plasma levels fell below 1X protein-adjusted IC90 between weeks 9 and 16, suggesting late viral breakthrough is unlikely. Conclusions: Using a stringent high-dose intravaginal SHIV challenge model where all control macaques became infected after one challenge, GSK744 LA administration protected 6 of 8 female macaques against three challenges. These results support further clinical development of GSK744 LA as PrEP in women at high risk for HIV-1 infection.